NL-Amsterdam-VUMC
NL-Amsterdam-VUMC
Amsterdam, Netherlands10 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL | diffuse large B-cell lymphoma, non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2026-09-23 | NCT03463057 | |
| A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-09-22 | NCT03839771 | |
| Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2025-08-19 | NCT07075016 | |
| A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2024-12-17 | NCT04027309 | |
| Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients | AML/MDS | Active, not recruiting | Phase 2 | 2024-09-19 | NCT04097470 | |
| Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2024-09-19 | NCT03541083 | |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 2 | 2024-02-14 | NCT03620578 | |
| Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 2 | 2023-11-01 | NCT03673826 | |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 2 | 2022-08-22 | NCT03645824 | |
| CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. | B-cell chronic lymphocytic leukemia | Active, not recruiting | Phase 2 | 2021-08-23 | NCT04639362 |